Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced it has been featured in a BioMedWire editorial titled "The Quest to Repair What Multiple Sclerosis Takes Away", which examines the urgent need for new treatment approaches for multiple sclerosis (MS). MS is a progressive neurological disease affecting over 2.9 million people worldwide, and current therapies only slow disease progression without stopping it completely.
The editorial highlights Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company is preparing to advance Lucid-MS into Phase 2 clinical trials, pursuing a novel approach that could potentially repair the underlying damage caused by the disease.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is researching Lucid-MS, a new chemical entity shown in preclinical models to prevent and reverse myelin degradation. Additionally, Quantum has developed UNBUZZD, an over-the-counter product for alcohol misuse, and retains a 19.84% stake in Unbuzzd Wellness Inc., along with royalty payments from sales.
The company's latest news and updates are available in its newsroom at https://ibn.fm/QNTM. BioMedWire, a specialized communications platform focusing on biotech and life sciences, is part of the Dynamic Brand Portfolio @ IBN and provides broad distribution and corporate communications solutions.
